This study is testing a new combination of drugs, **sacituzumab tirumotecan** and **pembrolizumab**, to see if they work better than current treatments for people with a specific type of breast cancer called **triple-negative breast cancer (TNBC)**. TNBC is a kind of breast cancer that does not have three common markers often found in breast cancer. The study is for people who had treatment but did not have a complete response in surgery. **Pathological complete response (pCR)** means no cancer is found in tissue samples after treatment. The study will check if the new drug combination can help patients live longer without the cancer coming back. **Invasive disease-free survival (iDFS)** means the cancer has not spread to other parts of the body.
- Participation involves receiving treatment as assigned and regular check-ups.
- The study is open-label, meaning both doctors and participants know which treatment is being given.
- Eligibility depends on factors including past treatments and health conditions.
How understandable was the trial content above?
Hard to understand
Easy to understand